The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: The mechanism of action of (±)pindolol

Neuropharmacology

Volumn 39, Issue 6, 2000, Pages 1044-1052

  Dawson, L A ^a   Nguyen, H Q ^a  

^a PFIZER INC   (United States)

Author keywords

( )Pindolol; 5 HT; 5 HT(1A); 5 HT(1B); Antagonist; Fluoxetine; Microdialysis

Indexed keywords

FLUOXETINE; ISAMOLTANE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; PINDOLOL; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; FRONTAL CORTEX; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; REGULATORY MECHANISM;

ANIMALS; AUTORECEPTORS; DRUG SYNERGISM; EXTRACELLULAR SPACE; FLUOXETINE; MALE; MICRODIALYSIS; OXADIAZOLES; PINDOLOL; PIPERAZINES; PROPANOLAMINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0034099924     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00192-6     Document Type: Article

References (43)

1. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of patients with depression treated with serotonin reuptake inhibitors. Archives of General Psychiatry. 51:1994;248-251.
2. Berman R.M., Darnell A.M., Miller H.L., Anand A., Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. American Journal of Psychiatry. 154:1997;37-43.
3. Blier P., De Montigny C., Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. Journal of Clinical Psychopharmacology. 7:1987;24-35.
4. Blier P., De Montigny C. Current advances and trends in the treatment of depression. Trends in Pharmacological Science. 15:1994;220-226.
5. Blier P., Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. Journal of Clinical Psychopharmacology. 15:1995;217-222.
6. Bordet R., Thomas P., Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. American Journal of Psychiatry. 155:1998;1346-1351.
7. Bosker F.J., Donker M.G., Klompmakers A.A., Kurata K., Westenberg H.G.M. 5-Hydroxytryptamine release in dorsal hippocampus of freely moving rats: modulation by pindolol. Progress in Neuropsychopharmacology and Biological Psychiatry. 18:1994;765-778.
8. 1A receptors in augmenting antidepressant activity in the mouse forced swimming test. Psychopharmacology. 136:1998;226-234.
9. Chaput Y., Blier P., De Montigny C. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn-Schmeidebergs Archiv für Pharmakology. 333:1986;342-348.
10. 1B/D receptor ligands. Pharmacological Therapy. 62:1994;385-405.
11. 1A autoreceptor in vivo. British Journal of Pharmacology. 124:1998;206-212.
12. 1B/D receptor antagonist. Neuroscience Letters. 188:1995;41-44.
13. Dawson L.A., Routledge C. Differential effects of potassium channel blockers on extracellular levels of serotonin and dopamine in the striatum of conscious rats. British Journal of Pharmacology. 116:1996;3260-3264.
14. 1A receptor antagonists on fluoxetine-induced changes in serotonin in rat frontal cortex. European Journal of Pharmacology. 345:1998;41-46.
15. 1A receptors. Neurochemistry Research. 21:1996;557-562.
16. 1A receptor antagonist, WAY100635. European Journal of Pharmacology. 281:1995;81-91.
17. 1A autoreceptors in the mechanism of action of serotonergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundamentals of Clinical Pharmacology. 10:1996;16-27.
18. 1B receptors with WAY100635 and GR127935. Journal of Neurochemistry. 68:1997;1159-1163.
19. 1D receptor subtypes. Trends in Pharmacological Science. 17:1996;103-105.
20. Hjorth S., Carlsson A. (-)-Pindolol stereospecifically inhibits rat brain serotonin (5-HT) synthesis. Neuropharmacology. 24:1985;1143-1146.
21. Hjorth S., Carlsson A. Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? European Journal of Pharmacology. 129:1986;131-138.
22. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. Journal of Neurochemistry. 60:1993;776-779.
23. Hjorth S. (-) Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. European Journal of Pharmacology. 303:1996;183-186.
24. 1A receptors or β-adrenoceptors, restrain the citalopram-induced increase in extracellular 5-hydroxytryptamine in vivo. European Journal of Pharmacology. 316:1996;43-47.
25. 1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI). Behavior and Brain Research. 73:1996;281-283.
26. 1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor. Neuropharmacology. 36:1997;461-465.
27. Hoyer D., Middlemiss D.N. The pharmacology of the terminal 5-HT autoreceptors in mammalian brain: evidence for species differences. Trends in Pharmacological Science. 10:1989;130-132.
28. Hyttel J. Pharmacological characterization of the selective serotonin reuptake inhibitors (SSRIs). International Clinical Psychopharmacology. 9:1994;19-26.
29. 1A receptors in the effects of acute and chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacology, Biochemistry and Behavior. 54:1996;143-147.
30. 1B receptors. Nature. 360:1992;161-163.
31. 1B receptors. Journal of Neurochemistry. 60:1993;380-383.
32. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, New York.
33. Perez V., Gilaberte I., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 349:1997;1594-1597.
34. 1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology. 15:1996;349-360.
35. 1A antagonist WAY100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neuroscience Letters. 219:1996;123-126.
36. Rutter J.J., Gundlah C., Auerbach S.B. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neuroscience Letters. 171:1994;183-186.
37. Sharp T., Bramwell S.R., Hjorth S., Grahame-Smith D.G. Pharmacological characterization of 8-OHDPAT induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis. British Journal of Pharmacology. 98:1989;989-997.
38. 1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. British Journal of Pharmacology. 121:1997;941-946.
39. 1D receptor antagonist. Behavior and Brain Research. 73:1996;157-161.
40. Tome M.B., Isaac M.T., Harte R., Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. International Clinical Psychopharmacology. 12:1997;81-89.
41. 1 receptor subtypes in the rat brain. Naunyn-Schmeidebergs Archiv für Pharmakologie. 337:1988;609-620.
42. Zanardi R., Artigas F., Franchini L., Sforzini L., Gasperini M., Smeraldi E., Perez J. How long should pindolol be associated with paroxetine to improve the antidepressant response? Journal of Clinical Psychopharmacology. 17:1997;446-450.
43. Zanardi R., Franchini L., Gasperini M., Lucca A., Smeraldi E., Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. Journal of Clinical Psychopharmacology. 18:1998;441-446.